Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

132.58 +0.59 (+0.45%)
Streaming Delayed Price Updated: 2:28 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Repligen: Q2 Earnings Insights ↗
  Repligen (NASDAQ:RGEN) reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Silk Road Medical Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗
Silk Road Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 90. 
Via Investor's Business Daily
News headline image
Tesla, Danaher And Some Other Big Gainers From Yesterday ↗
U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
News headline image
Recap: Repligen Q1 Earnings ↗
Repligen (NASDAQ:RGEN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
News headline image
Repligen's Q4 Earnings Beat Expectations, Issues Solid FY22 Guidance ↗
Repligen Corp (NASDAQ: RGEN)  
Via Benzinga
News headline image
Earnings Scheduled For February 17, 2022 ↗
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
News headline image
Earnings Scheduled For August 2, 2022 ↗
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. 
Via Benzinga
News headline image
This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday ↗
 Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered shares at an expected price of $5.00 per share with an insider lock-up period... 
Via Benzinga
News headline image
Thoughts For Thursday: Which Way Through Uncertainty? ↗
Markets are trying to maintain resistance levels generated from last week's rally, but finding the path to doing so is proving to be no easy matter. 
Via Talk Markets
News headline image
Why Is Super Micro Computer Higher By More Than 13%? 42 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected price of $5.00 per share with an insider lock-up period of 180 days ending... 
Via Benzinga
News headline image
Happy Birthday, iphone! ↗
Exactly a decade and a half ago to the day, what is now the staple of the smartphone market first hit the shelves. 
Via Talk Markets
News headline image
10 Biggest Price Target Changes For Thursday ↗
Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
38 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Earnings Scheduled For April 27, 2022 ↗
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
Repligen Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
Repligen (NASDAQ:RGEN) will host a conference call at 08:30 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Repligen (RGEN) Conference Call Follow this link to access the... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
News headline image
Elephant Tracking: How to Spot the Market’s Next Mega Winners BEFORE They Take Off ↗
If you follow an elephant's tracks, you find an elephant. If you follow a large money manager, you'll find the winners they've identified. 
Via InvestorPlace
News headline image
Repligen Earnings Perspective: Return On Capital Employed ↗
Pulled from Benzinga Pro data, Repligen (NASDAQ:RGEN) showed a loss in earnings since Q3, totaling $29.11 million. Sales, on the other hand, increased by 4.66% to $186.52 million during Q4. 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Friday ↗
Needham lowered Fiverr International Ltd. (NYSE: FVRR) price target from $205 to $100. Fiverr International shares gained 2% to $80.00 in pre-market trading. Wedbush cut the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
News headline image
This Foreboding Sign Looms Over Repligen's Chart ↗
If history is any guide, there may be trouble ahead for shares of Repligen (NASDAQ:RGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
News headline image
Repligen Stock Shows Leadership With 86 RS Rating ↗
A RS Rating upgrade for Repligen stock shows improving technical performance for the top-ranked firm in the Medical Products group. 
Via Investor's Business Daily
News headline image
Repligen Corp (RGEN) Q3 2021 Earnings Call Transcript ↗
RGEN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.